123 related articles for article (PubMed ID: 31433521)
1. MSH2 c.1022T>C, p.Leu341Pro is a founder pathogenic variation and a major cause of Lynch syndrome in the North of France.
Vermaut C; Leclerc J; Vasseur F; Wacrenier A; Lovecchio T; Boidin D; Rebergue MH; Cattan S; Manouvrier S; Lejeune S; Buisine MP
Genes Chromosomes Cancer; 2020 Feb; 59(2):111-118. PubMed ID: 31433521
[TBL] [Abstract][Full Text] [Related]
2. Characterization of new founder Alu-mediated rearrangements in MSH2 gene associated with a Lynch syndrome phenotype.
Pérez-Cabornero L; Borrás Flores E; Infante Sanz M; Velasco Sampedro E; Acedo Becares A; Lastra Aras E; Cuevas González J; Pineda Riu M; Ramón y Cajal Asensio T; Capellá Munar G; Miner Pino C; Durán Domínguez M
Cancer Prev Res (Phila); 2011 Oct; 4(10):1546-55. PubMed ID: 21778331
[TBL] [Abstract][Full Text] [Related]
3. A germline missense mutation in exon 3 of the MSH2 gene in a Lynch syndrome family: correlation with phenotype and localization assay.
Bianchi F; Maccaroni E; Belvederesi L; Brugiati C; Giampieri R; Bini F; Bracci R; Pagliaretta S; Del Prete M; Piva F; Mandolesi A; Scarpelli M; Berardi R
Fam Cancer; 2018 Apr; 17(2):215-224. PubMed ID: 28785832
[TBL] [Abstract][Full Text] [Related]
4. Mismatch repair gene mutation spectrum in the Swedish Lynch syndrome population.
Lagerstedt-Robinson K; Rohlin A; Aravidis C; Melin B; Nordling M; Stenmark-Askmalm M; Lindblom A; Nilbert M
Oncol Rep; 2016 Nov; 36(5):2823-2835. PubMed ID: 27601186
[TBL] [Abstract][Full Text] [Related]
5. Founder effect of a pathogenic MSH2 mutation identified in Spanish families with Lynch syndrome.
Menéndez M; Castellví-Bel S; Pineda M; de Cid R; Muñoz J; González S; Teulé A; Balaguer F; Ramón y Cajal T; Reñé JM; Blanco I; Castells A; Capellà G
Clin Genet; 2010 Aug; 78(2):186-90. PubMed ID: 20095990
[TBL] [Abstract][Full Text] [Related]
6. Frequency of rearrangements in Lynch syndrome cases associated with MSH2: characterization of a new deletion involving both EPCAM and the 5' part of MSH2.
Pérez-Cabornero L; Infante Sanz M; Velasco Sampedro E; Lastra Aras E; Acedo Becares A; Miner Pino C; Durán Domínguez M
Cancer Prev Res (Phila); 2011 Oct; 4(10):1556-62. PubMed ID: 21791569
[TBL] [Abstract][Full Text] [Related]
7. A unique MSH2 exon 8 deletion accounts for a major portion of all mismatch repair gene mutations in Lynch syndrome families of Sardinian origin.
Borelli I; Barberis MA; Spina F; Casalis Cavalchini GC; Vivanet C; Balestrino L; Micheletti M; Allavena A; Sala P; Carcassi C; Pasini B
Eur J Hum Genet; 2013 Feb; 21(2):154-61. PubMed ID: 22781090
[TBL] [Abstract][Full Text] [Related]
8. The nonsense mutation MSH2 c.2152C>T shows a founder effect in Portuguese Lynch syndrome families.
Pinheiro M; Francisco I; Pinto C; Peixoto A; Veiga I; Filipe B; Santos C; Maia S; Silva J; Pinto P; Santos R; Claro I; Lage P; Lopes P; Ferreira S; Rosa I; Fonseca R; Rodrigues P; Henrique R; Chaves P; Pereira AD; Brandão C; Albuquerque C; Teixeira MR
Genes Chromosomes Cancer; 2019 Sep; 58(9):657-664. PubMed ID: 30968502
[TBL] [Abstract][Full Text] [Related]
9. Microsatellite instability and novel mismatch repair gene mutations in northern Chinese population with hereditary non-polyposis colorectal cancer.
Sheng JQ; Chan TL; Chan YW; Huang JS; Chen JG; Zhang MZ; Guo XL; Mu H; Chan AS; Li SR; Yuen ST; Leung SY
Chin J Dig Dis; 2006; 7(4):197-205. PubMed ID: 17054581
[TBL] [Abstract][Full Text] [Related]
10. The founder mutation MSH2*1906G-->C is an important cause of hereditary nonpolyposis colorectal cancer in the Ashkenazi Jewish population.
Foulkes WD; Thiffault I; Gruber SB; Horwitz M; Hamel N; Lee C; Shia J; Markowitz A; Figer A; Friedman E; Farber D; Greenwood CM; Bonner JD; Nafa K; Walsh T; Marcus V; Tomsho L; Gebert J; Macrae FA; Gaff CL; Paillerets BB; Gregersen PK; Weitzel JN; Gordon PH; MacNamara E; King MC; Hampel H; De La Chapelle A; Boyd J; Offit K; Rennert G; Chong G; Ellis NA
Am J Hum Genet; 2002 Dec; 71(6):1395-412. PubMed ID: 12454801
[TBL] [Abstract][Full Text] [Related]
11. Muir-Torre Syndrome and founder mismatch repair gene mutations: A long gone historical genetic challenge.
Ponti G; Manfredini M; Tomasi A; Pellacani G
Gene; 2016 Sep; 589(2):127-32. PubMed ID: 26143115
[TBL] [Abstract][Full Text] [Related]
12. Lynch syndrome (hereditary nonpolyposis colorectal cancer) diagnostics.
Lagerstedt Robinson K; Liu T; Vandrovcova J; Halvarsson B; Clendenning M; Frebourg T; Papadopoulos N; Kinzler KW; Vogelstein B; Peltomäki P; Kolodner RD; Nilbert M; Lindblom A
J Natl Cancer Inst; 2007 Feb; 99(4):291-9. PubMed ID: 17312306
[TBL] [Abstract][Full Text] [Related]
13. A survey of the clinicopathological and molecular characteristics of patients with suspected Lynch syndrome in Latin America.
Rossi BM; Palmero EI; López-Kostner F; Sarroca C; Vaccaro CA; Spirandelli F; Ashton-Prolla P; Rodriguez Y; de Campos Reis Galvão H; Reis RM; Escremim de Paula A; Capochin Romagnolo LG; Alvarez K; Della Valle A; Neffa F; Kalfayan PG; Spirandelli E; Chialina S; Gutiérrez Angulo M; Castro-Mujica MDC; Sanchez de Monte J; Quispe R; da Silva SD; Rossi NT; Barletta-Carrillo C; Revollo S; Taborga X; Morillas LL; Tubeuf H; Monteiro-Santos EM; Piñero TA; Dominguez-Barrera C; Wernhoff P; Martins A; Hovig E; Møller P; Dominguez-Valentin M
BMC Cancer; 2017 Sep; 17(1):623. PubMed ID: 28874130
[TBL] [Abstract][Full Text] [Related]
14. Functional analysis of MSH2 unclassified variants found in suspected Lynch syndrome patients reveals pathogenicity due to attenuated mismatch repair.
Wielders EA; Hettinger J; Dekker R; Kets CM; Ligtenberg MJ; Mensenkamp AR; van den Ouweland AM; Prins J; Wagner A; Dinjens WN; Dubbink HJ; van Hest LP; Menko F; Hogervorst F; Verhoef S; te Riele H
J Med Genet; 2014 Apr; 51(4):245-53. PubMed ID: 24501230
[TBL] [Abstract][Full Text] [Related]
15. Constitutional Mismatch Repair Deficiency in Israel: High Proportion of Founder Mutations in MMR Genes and Consanguinity.
Baris HN; Barnes-Kedar I; Toledano H; Halpern M; Hershkovitz D; Lossos A; Lerer I; Peretz T; Kariv R; Cohen S; Half EE; Magal N; Drasinover V; Wimmer K; Goldberg Y; Bercovich D; Levi Z
Pediatr Blood Cancer; 2016 Mar; 63(3):418-27. PubMed ID: 26544533
[TBL] [Abstract][Full Text] [Related]
16. Lynch syndrome-associated mutations in MSH2 alter DNA repair and checkpoint response functions in vivo.
Mastrocola AS; Heinen CD
Hum Mutat; 2010 Oct; 31(10):E1699-708. PubMed ID: 20672385
[TBL] [Abstract][Full Text] [Related]
17. Haplotype analysis suggest that the MLH1 c.2059C > T mutation is a Swedish founder mutation.
von Salomé J; Liu T; Keihäs M; Morak M; Holinski-Feder E; Berry IR; Moilanen JS; Baert-Desurmont S; Lindblom A; Lagerstedt-Robinson K
Fam Cancer; 2018 Oct; 17(4):531-537. PubMed ID: 29288294
[TBL] [Abstract][Full Text] [Related]
18. Mismatch repair genes founder mutations and cancer susceptibility in Lynch syndrome.
Ponti G; Castellsagué E; Ruini C; Percesepe A; Tomasi A
Clin Genet; 2015 Jun; 87(6):507-16. PubMed ID: 25345868
[TBL] [Abstract][Full Text] [Related]
19. The MSH2 c.388_389del mutation shows a founder effect in Portuguese Lynch syndrome families.
Pinheiro M; Pinto C; Peixoto A; Veiga I; Mesquita B; Henrique R; Lopes P; Sousa O; Fragoso M; Dias LM; Baptista M; Marinho C; Mangold E; Vaccaro C; Evans DG; Farrington S; Dunlop MG; Teixeira MR
Clin Genet; 2013 Sep; 84(3):244-50. PubMed ID: 23170986
[TBL] [Abstract][Full Text] [Related]
20. Pathogenicity of A600V variant in exon 12 of the MSH2 gene detected in a Japanese kindred with Lynch syndrome.
Miyakura Y; Sugano K; Nomizu T; Lefor A; Yasuda Y
Jpn J Clin Oncol; 2012 Jan; 42(1):78-82. PubMed ID: 22086974
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
